Search reports, ask a question, or jump to a page.
The problem
Intervention: Monoclonal antibodies (nirsevimab, motavizumab, palivizumab) against RSV
Who it was tested with: Premature infants (11,319 total across 7 trials).
Children or communities are compared with a group that did not receive the intervention, or followed over years. This is the design that best separates what the intervention did from everything else that changed.
"This Network Meta-analysis (NMA) included 7 randomized controlled trials involving 4 drugs and 11319 infants." The network meta-analysis pooled evidence from multiple randomized controlled trials with control groups, providing experimental-level evidence of the efficacy and safety of RSV monoclonal antibodies in premature infants.
This is a network meta-analysis rather than direct head-to-head trials; the authors note that further studies are needed to confirm findings; no significant safety differences could be detected, which may reflect limited adverse event reporting in the included trials
Across countries and designs
9 studies · 17 countries
